Literature DB >> 23263930

Understanding infliximab in Crohn's disease: the long-term outcomes.

Dan Turner, Raffi Lev-Tzion.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23263930     DOI： 10.1007/s10620-012-2504-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  13 in total

1.  Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.

Authors:  Michael B Sprakes; Alexander C Ford; Lisa Warren; Dan Greer; John Hamlin
Journal:  J Crohns Colitis       Date:  2011-08-31       Impact factor: 9.071

2.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Authors:  S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts
Journal:  N Engl J Med       Date:  1997-10-09       Impact factor: 91.245

3.  Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.

Authors:  Edouard Louis; Jean-Yves Mary; Gwenola Vernier-Massouille; Jean-Charles Grimaud; Yoram Bouhnik; David Laharie; Jean-Louis Dupas; Hélène Pillant; Laurence Picon; Michel Veyrac; Mathurin Flamant; Guillaume Savoye; Raymond Jian; Martine Devos; Raphaël Porcher; Gilles Paintaud; Eric Piver; Jean-Frédéric Colombel; Marc Lemann
Journal:  Gastroenterology       Date:  2011-09-22       Impact factor: 22.682

4.  Infliximab for Crohn's disease: the first 500 patients followed up through 2009.

Authors:  Jennifer L Seminerio; Edward V Loftus; Jean-Frédéric Colombel; Prabin Thapa; William J Sandborn
Journal:  Dig Dis Sci       Date:  2012-09-29       Impact factor: 3.199

5.  Growth and clinical course of children with Crohn's disease.

Authors:  A M Griffiths; P Nguyen; C Smith; J H MacMillan; P M Sherman
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

6.  The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited.

Authors:  C I De Bie; T Z Hummel; A Kindermann; F T M Kokke; G M Damen; C M F Kneepkens; P F Van Rheenen; J J Schweizer; J H Hoekstra; O F Norbruis; W E Tjon A Ten; A C Vreugdenhil; J M Deckers-Kocken; C F M Gijsbers; J C Escher; L De Ridder
Journal:  Aliment Pharmacol Ther       Date:  2010-11-14       Impact factor: 8.171

7.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

8.  Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

Authors:  Jeffrey Hyams; Wallace Crandall; Subra Kugathasan; Anne Griffiths; Allan Olson; Jewel Johanns; Grace Liu; Suzanne Travers; Robert Heuschkel; James Markowitz; Stanley Cohen; Harland Winter; Gigi Veereman-Wauters; George Ferry; Robert Baldassano
Journal:  Gastroenterology       Date:  2006-12-03       Impact factor: 22.682

9.  Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.

Authors:  C H Seow; A Newman; S P Irwin; A H Steinhart; M S Silverberg; G R Greenberg
Journal:  Gut       Date:  2010-01       Impact factor: 23.059

10.  Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

Authors:  F Schnitzler; H Fidder; M Ferrante; M Noman; I Arijs; G Van Assche; I Hoffman; K Van Steen; S Vermeire; P Rutgeerts
Journal:  Gut       Date:  2008-10-02       Impact factor: 23.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.